Gelesis gelesis.com


Public lists: Pharma Startups (4732)

Gelesis is developing a smart pill (Gelesis100) to fulfill the unmet need for a product that can safely cause significant weight loss. Gelesis100 was developed for overweight and obese individuals as well as patients with impaired fasting glucose and diabetes who would particularly benefit from weight reduction but for whom weight loss is often a challenge. A safe, effective treatment for obesity and diabetes (two of the largest health problems in the world) would have a major impact on human he...Show all

Gelesis is developing a smart pill (Gelesis100) to fulfill the unmet need for a product that can safely cause significant weight loss. Gelesis100 was developed for overweight and obese individuals as well as patients with impaired fasting glucose and...Show all

Company (Alive / Active)

Phone: 617-391-9000

Fax:

501 Boylston Street
Suite 6102
Boston, 02116
Massachusetts, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Gelesis $115.6M Mar 1, 2018
See all 16 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Gelesis Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 8 investors

Competitors

Company Status Description Investors

Esperion Therapeutics

Ann Arbor, Michigan, United States
IPO / Went publicEsperion Therapeutics discovers and develops therapies for the treatment of cardiometabolic diseases. The company's lead product candidate, ETC-1002, is an AMP kinase activator and ATP citrate lyase inhibitor that is being evaluated in multiple Phase 2 clinical trials for the treatment of hypercholesterolemia and other cardiometabolic risk factors. Esperion intends to commercialize first-in-class therapies focused on enhancing lipid regulation, addressing statin intolerance and improving overall...Show allLogin to see details

Novacea

South San Francisco, California, United States
IPO / Went publicNovacea is a biopharmaceutical company that had been focused on in-licensing, developing and commercializing novel cancer therapies. Novacea has two product candidates, including AsentarTM, which had been in a Phase 3 clinical trial for androgen-independent prostate cancer, and AQ4N, a hypoxia-activated prodrug. There are currently no clinical trials planned or underway for either candidate.Login to see details
See all 16 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Methods for treating overweight or obesity Jun 19, 2015 Jan 02, 2018 Patent
Method for producing hydrogels Jun 07, 2012 May 31, 2016 Patent
Polymer hydrogels and methods of preparation thereof Feb 10, 2010 Feb 25, 2014 Patent
Method for treating constipation Apr 24, 2017 Application
Polymer hydrogels and methods of preparation thereof Jun 17, 2016 Application
See all 9 patents